Perspective Rational Cancer Treatment Combinations: An Urgent Clinical Need

被引:123
作者
Boshuizen, Julia [1 ]
Peeper, Daniel S. [1 ]
机构
[1] Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
关键词
KRAS-MUTANT LUNG; ACQUIRED-RESISTANCE; MEK INHIBITION; BREAST-CANCER; TARGETED THERAPY; ANTITUMOR IMMUNITY; BRAF INHIBITION; INTRATUMOR HETEROGENEITY; SYNTHETIC LETHALITY; TUMOR HETEROGENEITY;
D O I
10.1016/j.molcel.2020.05.031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We are witnessing several revolutionary technological advances in cancer. These innovations have not only contributed to a growing understanding of the tumor and its microenvironment but also uncovered an increasing array of new therapeutic targets. For most advanced cancers, therapy resistance limits the benefit of single-agent therapies. Therefore, some 5,000 clinical trials are ongoing globally to probe the clinical benefit of new combination treatments. However, the possibilities to combine individual treatments dramatically outnumber the patients available to enroll in clinical trials. This comes at a potential cost of missed opportunities, clinical failure, avoidable toxicity, insufficient patient accrual, and financial loss. A solution may be to design combination therapies more rationally, which are informed by fundamental biological and mechanistic insight. We will discuss some successes and failures of current treatment combinations, as well as interesting emerging preclinical concepts that warrant clinical exploration.
引用
收藏
页码:1002 / 1018
页数:17
相关论文
共 206 条
  • [91] Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
    Hong, Aayoung
    Moriceau, Gatien
    Sun, Lu
    Lomeli, Shirley
    Piva, Marco
    Damoiseaux, Robert
    Holmen, Sheri L.
    Sharpless, Norman E.
    Hugo, Willy
    Lo, Roger S.
    [J]. CANCER DISCOVERY, 2018, 8 (01) : 74 - 93
  • [92] Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
    Hu-Lieskovan, Siwen
    Mok, Stephen
    Moreno, Blanca Homet
    Tsoi, Jennifer
    Robert, Lidia
    Goedert, Lucas
    Pinheiro, Elaine M.
    Koya, Richard C.
    Graeber, Thomas G.
    Comin-Anduix, Begona
    Ribas, Antoni
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (279)
  • [93] HER kinase inhibition in patients with HER2-and HER3-mutant cancers
    Hyman, David M.
    Piha-Paul, Sarina A.
    Won, Helen
    Rodon, Jordi
    Saura, Cristina
    Shapiro, Geoffrey I.
    Juric, Dejan
    Quinn, David I.
    Moreno, Victor
    Doger, Bernard
    Mayer, Ingrid A.
    Boni, Valentina
    Calvo, Emiliano
    Loi, Sherene
    Lockhart, Albert C.
    Erinjeri, Joseph P.
    Scaltriti, Maurizio
    Ulaner, Gary A.
    Patel, Juber
    Tang, Jiabin
    Beer, Hannah
    Selcuklu, S. Duygu
    Hanrahan, Aphrothiti J.
    Bouvier, Nancy
    Melcer, Myra
    Murali, Rajmohan
    Schram, Alison M.
    Smyth, Lillian M.
    Jhaveri, Komal
    Li, Bob T.
    Drilon, Alexander
    Harding, James J.
    Iyer, Gopa
    Taylor, Barry S.
    Berger, Michael F.
    Cutler, Richard E., Jr.
    Xu, Feng
    Butturini, Anna
    Eli, Lisa D.
    Mann, Grace
    Farrell, Cynthia
    Lalani, Alshad S.
    Bryce, Richard P.
    Arteaga, Carlos L.
    Meric-Bernstam, Funda
    Baselga, Jose
    Solit, David B.
    [J]. NATURE, 2018, 554 (7691) : 189 - 194
  • [94] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
    Hyman, David M.
    Puzanov, Igor
    Subbiah, Vivek
    Faris, Jason E.
    Chau, Ian
    Blay, Jean-Yves
    Wolf, Juergen
    Raje, Noopur S.
    Diamond, Eli L.
    Hollebecque, Antoine
    Gervais, Radj
    Elena Elez-Fernandez, Maria
    Italiano, Antoine
    Hofheinz, Ralf-Dieter
    Hidalgo, Manuel
    Chan, Emily
    Schuler, Martin
    Lasserre, Susan Frances
    Makrutzki, Martina
    Sirzen, Florin
    Veronese, Maria Luisa
    Tabernero, Josep
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) : 726 - 736
  • [95] A Landscape of Pharmacogenomic Interactions in Cancer
    Iorio, Francesco
    Knijnenburg, Theo A.
    Vis, Daniel J.
    Bignell, Graham R.
    Menden, Michael P.
    Schubert, Michael
    Aben, Nanne
    Goncalves, Emanuel
    Barthorpe, Syd
    Lightfoot, Howard
    Cokelaer, Thomas
    Greninger, Patricia
    van Dyk, Ewald
    Chang, Han
    de Silva, Heshani
    Heyn, Holger
    Deng, Xianming
    Egan, Regina K.
    Liu, Qingsong
    Mironenko, Tatiana
    Mitropoulos, Xeni
    Richardson, Laura
    Wang, Jinhua
    Zhang, Tinghu
    Moran, Sebastian
    Sayols, Sergi
    Soleimani, Maryam
    Tamborero, David
    Lopez-Bigas, Nuria
    Ross-Macdonald, Petra
    Esteller, Manel
    Gray, Nathanael S.
    Haber, Daniel A.
    Stratton, Michael R.
    Benes, Cyril H.
    Wessels, Lodewyk F. A.
    Saez-Rodriguez, Julio
    McDermott, Ultan
    Garnett, Mathew J.
    [J]. CELL, 2016, 166 (03) : 740 - 754
  • [96] INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH
    ISHIDA, Y
    AGATA, Y
    SHIBAHARA, K
    HONJO, T
    [J]. EMBO JOURNAL, 1992, 11 (11) : 3887 - 3895
  • [97] Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
    Jain, Rajul K.
    Lee, J. Jack
    Hong, David
    Markman, Maurie
    Gong, Jing
    Naing, Aung
    Wheler, Jennifer
    Kurzrock, Razelle
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (04) : 1289 - 1297
  • [98] Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
    Jespersen, Henrik
    Lindberg, Mattias F.
    Donia, Marco
    Soderberg, Elin M. V.
    Andersen, Rikke
    Keller, Ulrich
    Ny, Lars
    Svane, Inge Marie
    Nilsson, Lisa M.
    Nilsson, Jonas A.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [99] VISTA is an acidic pH-selective ligand for PSGL-1
    Johnston, Robert J.
    Su, Linhui Julie
    Pinckney, Jason
    Critton, David
    Boyer, Eric
    Krishnakumar, Arathi
    Corbett, Martin
    Rankin, Andrew L.
    Dibella, Rose
    Campbell, Lynne
    Martin, Gaelle H.
    Lemar, Hadia
    Cayton, Thomas
    Huang, Richard Y. -C.
    Deng, Xiaodi
    Nayeem, Akbar
    Chen, Haibin
    Ergel, Burce
    Rizzo, Joseph M.
    Yamniuk, Aaron P.
    Dutta, Sanjib
    Ngo, Justine
    Shorts, Andrea Olga
    Ramakrishnan, Radha
    Kozhich, Alexander
    Holloway, Jim
    Fang, Hua
    Wang, Ying-Kai
    Yang, Zheng
    Thiam, Kader
    Rakestraw, Ginger
    Rajpal, Arvind
    Sheppard, Paul
    Quigley, Michael
    Bahjat, Keith S.
    Korman, Alan J.
    [J]. NATURE, 2019, 574 (7779) : 565 - +
  • [100] Epigenetic therapy in immune-oncology
    Jones, Peter A.
    Ohtani, Hitoshi
    Chakravarthy, Ankur
    De Carvalho, Daniel D.
    [J]. NATURE REVIEWS CANCER, 2019, 19 (03) : 151 - 161